Orexigen Therapeutics, Inc. (OREX)
-NasdaqGS 6.38 
0.10(1.54%) 1:59PM EDT - Nasdaq Real Time Price
| Prev Close: | 6.48 |
|---|
| Open: | 6.46 |
|---|
| Bid: | 6.37 x 1100 |
|---|
| Ask: | 6.38 x 600 |
|---|
| 1y Target Est: | 10.57 |
|---|
| Beta: | 2.69 |
|---|
| Next Earnings Date: | 7-Aug-13 |
|---|
| Day's Range: | 6.30 - 6.47 |
|---|
| 52wk Range: | 3.10 - 7.73 |
|---|
| Volume: | 555,161 |
|---|
| Avg Vol (3m): | 1,127,500 |
|---|
| Market Cap: | 603.82M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.29 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Why This Obesity Drug Is the Sector's Best Betat Motley Fool(Fri 10:27AM EDT)
- Arena - Good Sales, Bad Sales, Long And Shortat Seeking Alpha(Fri 2:53AM EDT)
- Commit To Purchase Orexigen Therapeutics At $3, Earn 23.3%at TheStreet(Thu, May 23)
- 5 Stocks Under $10 Set to Soarat TheStreet(Thu, May 23)
- 3 Pipeline Obesity Treatments You Should Watchat Motley Fool(Wed, May 22)
- Orexigen Therapeutics' CEO Presents at 2013 UBS Global Healthcare Services Conference (Transcript)at Seeking Alpha(Wed, May 22)
- The 9 Most Obese Countries in the Worldat Motley Fool(Mon, May 20)
- Orexigen Therapeutics to Present at the UBS Global Healthcare ConferencePR Newswire(Fri, May 17)
- Due Diligence in Finding the Value of Pharmaceuticals: Expert Portfolio Manager Finny Kuruvilla Discusses His Portfolio Construction Strategy with The Wall Street TranscriptWall Street Transcript(Thu, May 16)
- Orexigen Therapeutics' Management Presents at Bank of America Merrill Lynch Health Care Conference - Transcriptat Seeking Alpha(Wed, May 15)
- Weight Loss Isn't Just for Looking Good Anymoreat Motley Fool(Wed, May 15)
- OREXIGEN THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Wed, May 15)
- Will Obesity Drugs Gain Soon?at Motley Fool(Wed, May 15)
- Looking at Arena Following Sell-Offat Motley Fool(Tue, May 14)
- Vivus Starting To Gain The Advantage Over Arenaat Seeking Alpha(Tue, May 14)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 178.90 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.79 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.19 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | -0.51 |
|---|
Business Summary
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity.
View More